C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit C4 Therapeutics is seeking a highly motivated and innovative scientist to apply cutting edge structural biology techniques to the discovery, characterization, and development of small molecule targeted protein degraders. You will leverage your extensive experience and in-depth knowledge of how structural biology, biochemistry, and biophysics can be creatively and successfully applied to challenging drug discovery and development efforts. You will manage external CROs to support mechanistic understanding and optimization of monovalent and bivalent molecules that promote ternary complex formation between E3 ligases and drivers of disease leading to their efficient ubiquitination and degradation. This role gives you the opportunity to collaborate closely with lead discovery biologists as well as computational and medicinal chemists to support a broad portfolio of heterobifunctional and molecular glue degrader projects from hit finding through hit-to-lead, and lead optimization stage. Your work will be key to the evolution and enhancement of our degrader discovery platform.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Principal
Education Level
Ph.D. or professional degree
Number of Employees
101-250 employees